ABG Stock Overview
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 3/6 |
Past Performance | 1/6 |
Financial Health | 2/6 |
Dividends | 3/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Cencora, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$238.30 |
52 Week High | US$248.55 |
52 Week Low | US$196.78 |
Beta | 0.50 |
1 Month Change | -1.63% |
3 Month Change | -0.084% |
1 Year Change | 10.48% |
3 Year Change | 72.68% |
5 Year Change | 205.51% |
Change since IPO | 968.61% |
Recent News & Updates
Recent updates
Shareholder Returns
ABG | DE Healthcare | DE Market | |
---|---|---|---|
7D | -3.3% | -0.7% | 0.4% |
1Y | 10.5% | 35.4% | 12.0% |
Return vs Industry: ABG underperformed the German Healthcare industry which returned 37% over the past year.
Return vs Market: ABG underperformed the German Market which returned 15.4% over the past year.
Price Volatility
ABG volatility | |
---|---|
ABG Average Weekly Movement | n/a |
Healthcare Industry Average Movement | 5.2% |
Market Average Movement | 5.2% |
10% most volatile stocks in DE Market | 11.7% |
10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: ABG's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine ABG's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1871 | 44,000 | Bob Mauch | www.cencora.com |
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company’s U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Cencora, Inc. Fundamentals Summary
ABG fundamental statistics | |
---|---|
Market cap | €46.26b |
Earnings (TTM) | €1.28b |
Revenue (TTM) | €277.48b |
36.2x
P/E Ratio0.2x
P/S RatioIs ABG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ABG income statement (TTM) | |
---|---|
Revenue | US$303.19b |
Cost of Revenue | US$293.30b |
Gross Profit | US$9.90b |
Other Expenses | US$8.50b |
Earnings | US$1.40b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 7.20 |
Gross Margin | 3.26% |
Net Profit Margin | 0.46% |
Debt/Equity Ratio | 2,251.6% |
How did ABG perform over the long term?
See historical performance and comparisonDividends
0.8%
Current Dividend Yield29%
Payout RatioCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/03/12 00:33 |
End of Day Share Price | 2025/03/11 00:00 |
Earnings | 2024/12/31 |
Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cencora, Inc. is covered by 39 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
David Toung | Argus Research Company |
Gregory Bolan | Avondale Partners |
Eric Coldwell | Baird |